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INTRODUCTION: 
Drug promotion refers to all the information and 
persuasive activities by manufacturers and distributors in 
order to induce the prescription, supply, purchase and/or 
use of medicinal drugs. There is evidence that drug 
utilization problems are increasingly encountered in many 
developing countries due to unethical practices of 
pharmaceutical promotion. 
According to the World Health Organization (WHO), 
medicinal drug promotion should be reliable, accurate, 
truthful, informative, balanced, up–to–date and capable of 
substantiation. Text and illustration contents should be 
consistent with scientific information.1 Pharmaceutical 
companies are in the business of developing and selling 
new drugs. These are accepted in health care system 
through health care professionals, and its availability is of 
little value unless the prescriber is aware of its existence 
and has scientific information to use it effectively.2 The 
pharmaceutical industry in US spent over $11 billion in 
pharmaceutical marketing, excluding medication samples, 
in 2004, with more than $7 billion directed to clinicians.3 
Drug advertisement is an effective tool to form 
physicians' perception of drug efficacy and prescription 
behavior.4-7 Advertisement claims of pharmaceutical 
companies have been criticized for making exaggerated 
claims, emphasizing relative over absolute effect 
measures,8 omission of adverse effects, and for use of 
different standards for promoting drugs in resource-
limited countries.9 Pharmaceutical sales representatives 
(medical representatives) frequently visit 70% to 90% of 
physicians during their daily clinical practice and many 
consider the promotional printed material to be a major 
source of clinical information.10 
One of the well-known promotional activities of 
pharmaceutical industries is to produce advertising 
brochures which at times are inaccurate and of poor 
educational value.9,11,12 These promotional activities 
create the potential for inappropriate prescribing practices 
by influencing physicians' prescribing behavior without 
necessarily benefiting the patients 13-15 but contributes to 
increased health care costs.16 Non–ethical medicinal drug 
promotion is a major issue worldwide leading to irrational 
drug use, overprescription, self–medication and drug 
abuse.7,17,18 This is a more serious issue in developing 
countries.  
This study was conducted to find out the accuracy of 
promotional drug literature presented to prescribers by 
using "WHO criteria for ethical medicinal drug 
promotion, 1988".1 
MATERIAL AND METHODS: 
This observational, cross-sectional study was conducted 
in the Psychiatric outpatient department (OPD) of 
Chitwan School of Medical Sciences, a tertiary care 
hospital at Bharatpur, Chitwan, Nepal, after its approval 
by Institutional Ethics Committee. More than hundred 
fifty of brochures were collected from the period 1st 
February 2011 to 31st July 2011. Collected brochures 
were then explored to exclude the following materials: 
Literature promoting medicinal devices and equipments, 
ayurvedic medicines, drug monographs, reminder 
advertisements (reminder advertisements do not present 
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any therapeutic information and have different criteria for 
evaluation).1  
WHO criteria for ethical medicinal drug promotion 
dictate that promotional literature should contain the 
following informations.1 
1. The name(s) of the active ingredient(s) using either 
international nonproprietary names (INN) or the 
approved generic name of the drug. 
2. The brand name 
3. Amount of active ingredient(s) per dose 
4. Other ingredients known to cause problems, i.e. 
adjuvant 
5. Approved therapeutic uses 
6. Dosage form or dosage schedule 
7. Side effects and major adverse drug reactions,  
8. Precautions, contraindications and warnings,  
9. Major drug interactions 
10. Name and address of manufacturer or distributor 
11. Reference to scientific literature as appropriate 
RESULTS: 
A total of seventy one drug promotional brochures were 
evaluated from different manufacturers. The majority of 
promotional materials were from Indian companies or 
multinational companies based in India. The 
manufacturer’s name was not mentioned in eleven (15.50 
%) of the promotional materials. The therapeutic 
classifications of the drugs promoted in the promotional 
material are mentioned in Table 1 and analysis of the 
pharmaceutical information present in the promotional 
materials is described in Table 2.  
 
Table 1: Therapeutic groups of the drugs 
Anti -
depressant 
Venlafaxine Escitalopram Fluoxetine Sertraline Mitrazapine 
 Amitriptyline Olanzapine Imipramine Paroxetine 
Anti -
convulsant 
Sodium valproate and valproic acid  Clonazepam Lamotrigene Levetiracetam 
Carbamazepine Quetiapine Pregabaline  
Anti-psychotic Risperidone Aripiprazole Lithium carbonate 
Others Donepezil Flunarazine  
 
Table 2: Availability of pharmaceutical information in the promotional materials 
WHO criteria for ethical medicinal drug promotion Psychotropic Agents % age  
1. The name(s) of the active ingredient(s) using either international nonproprietary 
names   (INN) or the approved generic name of the drug. 
62 87.32 
2. The brand name 71 100 
3. Amount of active ingredient(s) per dosage form 63 88.73 
4. Other ingredients known to cause problems, i.e. adjuvant 0 0 
5. Dosage form or dosage schedule  55 77.46  
6. Approved therapeutic uses 59 83.10 
7. Side effects and major adverse drug reactions  8 11.27 
8. Precautions, contraindications and warnings 7 9.86 
9. Major drug interactions 6 8.45 
10. Name and address of manufacturer or distributor 60 84.50 
11. Reference to scientific literature as appropriate 9 12.67 
 
DISCUSSION: 
It was found from this study that there are deficiencies in 
drug information of the advertised drugs in Nepal. 
Pharmaceutical industries did not follow WHO guidelines 
while promoting their drug products, thus accelerated 
their commercial motive rather than ethical educational 
aspect. The promotional brochures were full of 
unsubstantiated claims regarding safety or efficacy, and 
those claims were therapeutically irrelevant also. 
Important informations regarding adverse drug reactions, 
contraindications, or drug interactions were usually 
missing. Reference citations were given to earn 
credibility, but it was difficult to trust them because of 
ambiguous presentation, poor quality, and questionable 
retrievability. Therapeutically unrelated matter was 
printed, compromising the space to be given to important 
brief prescription information. 
In this study, general information like name(s) of the 
active ingredient(s) using either international 
nonproprietary names (INN) or the approved generic 
name of the drug was mentioned on most of 
advertisements (n=62, 87.32%), This was a similar 
finding to the study performed in Nepal 19, Thailand ( 
88%).20 This study showed that the among the entire 
advertisements only 88.73% (n=63) brochure contained 
amount of active ingredient(s) per dosage form which is 
slightly higher than the study which contained 81.82%19 
while none of the brochure contained other ingredients 
known to cause problems. In another study of the 
advertising material and marketing brochures sent out by 
drug companies to physician in Pakistan also showed 
about only 4% brochures contained the information.21 In 
the similar studies performed in western Nepal none of 
the promotional brochure has other ingredients known to 
cause problems. 
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Likewise, in this study, approved  therapeutic indications 
and safety profile like side effects or major adverse drug 
reactions were outlined in 83.10% (n=59) and 11.27% 
(n=8) of promotional drug brochures respectively where 
indications are similar to the studies in Laos (100%), 
Thailand (91.2%), Vietnam (86.4%),20 and Pakistan 
(86.95%)
21 
while the safety profile is much less compared 
to the studies in Laos (39.2%), Thailand (43.6%),Vietnam 
(55.6%)20and Pakistan (47.82).21 
Drugs promotion brochure containing dosage form and 
manufacture’s name and address in our study were 
observed to be 77.46% (n=55) and 84.50% (n=60) 
respectively, which is comparatively higher than the 
studies observed in Laos [dosage form (56.1 %), 
manufacturer name (39.2%)], Thailand [dosage form 
(59%), manufacturer name (76.2%)].20 and Pakistan.21 
The enormity of inappropriate drug advertisement is 
likely to be higher in developing countries, where policy 
on drug advertisement is weak and the appropriate 
structures to monitor advertisement are lacking. In Nepal 
where drug advertisement guidelines are similar to those 
of WHO, deviation from the guidelines was quite obvious 
in this study. This deviation may have resulted from 
weakness in implementing drug advertisement policy in 
Nepal by the department of drug administration (DDA) 
and lack of mechanism to monitor drug promotional 
campaign by the pharmaceutical companies. 
Drug advertisement with inadequate information for 
appropriate prescribing contradicts the policy of 
pharmaceutical companies.22 The lack of training of 
neurophysicians in evaluating drug adverts for 
appropriate prescribing information could lead to 
inappropriate prescribing. The lack of serious sanctions is 
a feature of self-regulatory systems of advertising 
control.23 Ironically, misleading drug promotion has 
appeared to be a vicious circle between the drug 
companies and health professionals that does more harm 
than good worldwide.24 Various studies reported variable 
rates of misleading claims in the printed promotional 
materials. The time needed for the individual doctor to 
critically appraise the advertised drug is usually not 
available and they may lack the skills required.12 
Therefore, formal teaching of doctors in their 
undergraduate training in pharmacology, in the art of 
critical appraisal of drug advertisement needs to be 
addressed.  
CONCLUSION: 
From this study it is concluded that none of the 
promotional material in Nepal exactly follows the WHO’s 
Ethical Criteria for Medicinal Drug Promotion. Safety 
profile like side effects or major adverse drug reactions, 
precautions, major drug interactions are missing from 
most of the promotional materials. Pharmaceutical 
advertisements subtly influence the prescribing behavior 
of health providers and therefore affect the end user of 
these drugs, the patient.  
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